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Introduction
At least 25% of patients with breast cancer develop skele-
tal metastases, with bone the site of disease producing
the greatest morbidity. Skeletal complications include
hypercalcaemia, pathological fracture, bone pain requiring
radiotherapy, and spinal cord or nerve root compression.
Randomised trials in advanced breast cancer have shown
that one of these major events occurs, on average, every
3–4 months [1,2]. The average life expectancy from diag-
nosis of bone metastases is 2 years, with up to 20% of
patients surviving 5 years. There is thus a real need for
treatment to reduce skeletal complications and to improve
the quality of life in these individuals.
Bone is not an inert organ; normal bone undergoes a con-
tinuous process of resorption and formation. Recent
research has begun to shed new light on the development
of bone metastases, as well as on the continual interaction
between cancer cells and active bone. Tumour cells in the
bone marrow cavity secrete a variety of paracrine factors
that stimulate bone formation. Of key importance is the stim-
ulation of osteoclast function. This results in osteolysis,
which is typically associated with disruption of the normal
coupling signals that control the relative levels of osteoblast
and osteoclast function. It is in this situation that bisphos-
phonates are able to offer their therapeutic potential in
metastatic disease. These abnormalities in bone function
are reflected in abnormal levels of serum and urinary colla-
gen breakdown products, which may therefore be exploited
as biochemical markers to monitor progress of the disease
and the effectiveness of bisphosphonate therapy.
The breast cancer patient with skeletal metastases now
has a much improved range of management options,
including radiotherapy and radiopharmaceuticals,
orthopaedic surgery and systemic anticancer therapy with
cytotoxic and endocrine therapy [3]. Nevertheless, it is
now apparent that the bisphosphonates present an impor-
tant additional treatment strategy that can reduce both the
symptoms and complications of bone metastases.
Bisphosphonates used in oncology
All bisphosphonates contain a phosphorus–carbon–phos-
phorus central structure that promotes their binding to the
bone matrix, and variable side chains that determine the
specific effects on bone cells. Although a large number of
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candidate compounds are potentially available, and there is
continuing interest in the development of new compounds,
a relatively small number of bisphosphonates have so far
been introduced into routine clinical use in oncology prac-
tice. Clodronate (usually given by mouth) and pamidronate
(by intravenous infusion) are the two drugs most commonly
prescribed for oncological indications.
It is known that less than 5% of the dose of oral clo-
dronate is absorbed (Fig. 1) [3] and this leads to problems
in compliance (taking the size and number of capsules
required to maintain a therapeutic dose). A significant pro-
portion of patients also experience gastrointestinal toxicity,
which is more common than with intravenous prepara-
tions. Infusion of pamidronate typically takes 1–2 hours,
placing additional demands on already overworked intra-
venous therapy units.
Clinical trials with two relatively new bisphosphonates,
zoledronic acid and ibandronate, suggest that they may
soon find a place in routine therapy. Zoledronic acid, which
is given intravenously, shows much greater potency than
the earlier bisphosphonate drugs in vitro, and infusion
times are dramatically reduced (15 min). Zoledronic acid
has yielded impressive results in the treatment of hypercal-
caemia and bone pain associated with bone metastases
[4], and is at least as effective as pamidronate in the pre-
vention of skeletal morbidity from breast cancer [5,6].
Ibandronate is an amino-bisphosphonate that is also highly
potent and is now licensed in Europe for the treatment of
hypercalcaemia of malignancy. Ibandronate also appears
to offer benefit in the treatment and prevention of osteo-
porosis, and in reduction in skeletal morbidity in metastatic
bone disease [7]. As well as the intravenous form, an oral
preparation is being developed that appears to be well
tolerated at a therapeutically useful dose [8].
The use of bisphosphonates in 
tumour-induced hypercalcaemia
Hypercalcaemia is the most common metabolic complica-
tion of malignancy and it is important to recognise
because it is associated with a range of unpleasant
gastrointestinal and neurological side effects. Hypercal-
caemia frequently responds well to treatment, at least in
the short term, which can significantly improve a patient’s
quality of life.
The pathophysiology depends on several factors including
local osteolysis by tumour cells and more generalised
osteolysis by humoral factors. Parathyroid hormone related
protein levels are often raised in patients with hypercal-
caemia and appear to have an important role in humoral
hypercalcaemia of malignancy [9]. Renal effects, including
increased renal tubular reabsorption of calcium and
impaired renal glomerular filtration, also contribute [3].
Bisphosphonates, since their introduction, have revolu-
tionised the treatment of hypercalcaemia, and an intra-
venous bisphosphonate together with rehydration is now
the standard treatment of hypercalcaemia of malignancy.
Generally, bisphosphonates need to be given intra-
venously to allow restoration of normocalcaemia, although
clodronate can be given subcutaneously and this can be
useful in the pallative care setting. Intravenous clodronate
as a single infusion of 1500 mg can achieve normocal-
caemia in 80% of patients [9]. Similar studies with
pamidronate given as a single infusion over 2–24 hours
have shown that normocalcaemia can be achieved in up to
90% of patients [9].
Newer and potentially more potent bisphosphonates such
as zoledronic acid may be even more effective and,
because of their shorter infusion time, may simplify treat-
ment. A recent pooled analysis of two randomised, con-
trolled trials compared intravenous zoledronic acid (doses
of 8 and 4 mg) with pamidronate (90 mg) in hyper-
calcaemia of malignancy [4]. After 10 days, both
zoledronic acid arms of the trial showed a better complete
response rate (8 mg, 88.4%; 4 mg, 86.7%) compared
with the pamidronate arm (69.7%). The response duration
was also better in the zoledronic acid arms of the trial (43
and 32 days) compared with the pamidronate arm
(18 days).
Bisphosphonates for bone pain
External beam radiotherapy remains the treatment of
choice for many patients with well-localised bone pain,
Figure 1
Pharmacokinetics of bisphosphonates showing the skeletal retention
and poor oral availability of currently available compounds.
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with excellent results achieved in most situations with a
short treatment schedule of one to five fractions. However,
patients often have widespread, poorly localised, non-
mechanical pain, and other patients experience recurrent
pain in previously irradiated sites. For this group of
patients, bisphosphonates provide a useful alternative
treatment option.
Most experience with bisphosphonates for bone pain is
from their use for skeletal metastases in advanced breast
cancer, although the effects of bisphosphonates on pain
seem to be independent of the nature of the underlying
tumour or radiographic appearance of the metastases,
with sclerotic lesions responding similarly to lytic metas-
tases. Studies with the currently available oral bisphos-
phonates (at doses tested) have been disappointing; none
have convincingly been shown to alleviate metastatic bone
pain in a clinically significant manner [9,10] in the absence
of systemic anticancer therapy. To obtain a useful effect,
the intravenous route is necessary at least until more
potent oral formulations are available. Several studies
using intravenous clodronate, ibandronate, pamidronate
and zoledronic acid have all demonstrated useful pain
relief with improvements in analgesia requirements and an
improved quality of life [7,9,11].
A randomised, double-blind trial to evaluate the contribu-
tion of markers of bone resorption in patients with bone
metastases was carried out by Vinholes et al. [12]. Symp-
tomatic decrease in bone pain was seen after administra-
tion of pamidronate but not placebo, and the response
correlated well with a decrease in bone resorption
markers, particularly Ntx (N-terminal telopeptide of type I
collagen). It appeared to be necessary to normalise bone
resorption markers to achieve optimal pain relief and this
should be the aim of bisphosphonate therapy. Those indi-
viduals who had an initial level of bone resorption markers
greater than twice the upper normal limit responded very
poorly to pamidronate and this may have useful predictive
value for therapy.
Two recent studies have highlighted the apparent
advantage of intravenous over oral bisphosphonates in
pain reduction. A study by Diel et al. [13] over a period
of 2 years with 361 patients treated with oral clo-
dronate, intravenous clodronate, or intravenous
pamidronate showed the best pain reduction was
achieved by intravenous therapy. In a study in our own
centre, 51 patients with metastatic bone disease were
randomly allocated to treatment with oral clodronate,
intravenous clodronate followed by the same schedule
of oral clodronate, or intravenous pamidronate. There
was a significantly greater improvement in pain scores
in the intravenous pamidronate arm of the trial, and this
was reflected in an accompanying improvement in bone
resorption markers [10].
The optimum dose and choice of bisphosphonate may
depend on the stage of the disease, and individual
response in bone markers may play an increasingly
important role in the future in tailoring treatment to the
individual patient.
The use of bisphosphonates in limiting
skeletal complications of bone metastases
There is now overwhelming evidence that bisphosphonate
therapy reduces skeletal complications in breast cancer,
such that it should now be considered part of standard
cancer therapy. Data from some of the many clinical trials
to assess the effects of bisphosphonates (particularly clo-
dronate and pamidronate) on skeletal-related events are
summarised in Table 1.
Randomised trials comparing chemotherapy + pamidronate
with chemotherapy + placebo were particularly striking,
with a significant reduction in the mean number of skeletal
related events per year in the pamidronate arm of the trials
[14,15]. Such trials also demonstrated that a reduction in
skeletal morbidity began to be apparent after 3 months of
treatment with bisphosphonates and was maintained
throughout the study period. In addition, quality of life was
maintained and a reduction in pain and analgesic use was
observed compared with the placebo group. In one study
by Hortobagyi et al. [2] there was a significant reduction in
the proportion of patients having any skeletal related
events (43% versus 56%), a reduction in the number of
non-vertebral pathological fractures (by 60%), and a
reduction in the proportion of patients having radiation to
bone (by 45%) or surgery on bone (by 52%).
These trials led to the worldwide registration of
pamidronate for treatment of metastatic breast cancer. A
randomised, double-blind, dose-finding phase II study of
zoledronic acid [5] has led to a phase III study using
4–8 mg for the treatment of osteolytic metastases, includ-
ing breast cancer, the results of which are awaited.
In patients with metastatic breast cancer, bisphosphonates
have not yet shown any significant overall effects on patient
survival, although subgroup analyses have suggested that
young (<50 years) patients with breast cancer receiving
chemotherapy may gain a small survival advantage [1,16].
Recent research has focused on optimising the treatment
parameters. Of particular importance is the need for trial
evidence regarding the most appropriate time to initiate
bisphosphonate treatment and its optimum duration. It
would be extremely useful to be able to predict whether a
particular patient is likely to respond to bisphosphonate
treatment. It seems possible that biochemical markers of
bone resorption may be useful in this respect, and there is
evidence that patients who fail to normalise bone resorp-
tion markers experience a higher number of skeletal events.
In one study of 21 patients with raised bone markers
receiving pamidronate [17], 12 patients normalised the
rate of bone resorption. The normalised group showed a
significant reduction in progression of their skeletal metas-
tases (P = 0.03), compared with the remaining nine
patients whose bone resorption remained abnormal. In the
group that normalised, there was also a reduction in frac-
ture rate that approached, but did not reach, significance
(P = 0.07) in this small study.
Osteoporosis in cancer patients
There are now increasing numbers of long-term survivors
who have received combination chemotherapy, radiother-
apy and hormonal cancer treatment. Many of these individ-
uals are at increased risk of osteoporosis, largely because
of the endocrine changes induced by such therapy. This is
a particularly important long-term problem in women with
breast cancer for whom there are concerns about the
safety of hormone replacement therapy. In such patients,
bisphosphonates represent an effective alternative therapy
both to prevent and to treat osteoporosis, and biphospho-
nates should be seriously considered particularly in those
experiencing an early menopause [18].
Prevention or delay of bone metastases
Since the release of growth factors and cytokines from
resorbing bone are known to facilitate cancer cell growth
and proliferation at the bone surface, the known effects of
bisphosphonates in reducing bone resorption might be
expected to inhibit initiation and progression of metastatic
bone disease. After encouraging animal studies, several
human trials have been carried out with the bisphospho-
nate clodronate. The clinical benefit is far from clear at
present, however, due to apparently conflicting results. In a
study of 1079 women with primary operable breast cancer,
only 28 (5.2%) patients on clodronate developed definite
bone metastases compared with 44 (8.1%) on placebo,
with a mean follow-up of 4 years (P = 0.054) [19].
Diel et al. [20] studied a group of 302 primary breast
cancer patients who had no overt evidence of metastatic
disease but who had tumour cells in the bone marrow, a
risk factor for development of distant metastases. Patients
were randomly assigned to receive oral clodronate for
2 years (157 patients) or standard follow-up (145
patients). The median observation period was 36 months.
The incidence of osseous metastases was significantly
lower in the clodronate group (11 patients versus 25
patients; P < 0.002) and there was also an unexpected
reduction in the incidence of visceral metastases in the
clodronate group (19 patients versus 42 patients;
P < 0.001).
This potentially exciting finding must, however, be viewed
in the light of a further trial that suggested quite the
reverse. Saarto et al. [21] randomised a group of 299
women with primary node-positive breast cancer to clo-
dronate (149 patients) and to control (150 patients), with
a follow-up of 5 years for all patients. Bone metastases
were detected equally often in the clodronate group (29
patients) and the control group (24 patients) (P = 0.27),
the development of non-skeletal recurrence was signifi-
cantly higher in the clodronate group (60 patients versus
36 patients; P = 0.0007) and, most importantly, the overall
survival was significantly lower in the clodronate group
(70% versus 83%; P = 0.009).
Identifying a definite adjuvant role for bisphosphonates will
therefore require further large, randomised studies to
resolve these and other issues. Until the results of further
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Table 1
Effects of bisphosphonate treatment on skeletal morbidity: results of randomised trials
Agent and route n Results (no bisphosphonate versus bisphosphonate treated) Reference
Pamidronate, 600 mg orally daily 161 Reduced SMR, 94 vs 52 events/100 women years (P < 0.01) van Holten-Verzantvoort et al. [24]
600 mg poorly tolerated; no benefit with reduced dose (300 mg)
Clodronate, 1600 mg orally daily 173 Reduced SMR, 305 vs 219 events/100 woman years (P < 0.001) Paterson et al. [25]
Pamidronate, 45 mg intravenously 295 Increased time to bone progression, 168 vs 249 days (P = 0.02) Conte et al. [14]
3 weekly
Pamidronate, 90 mg intravenously 382 Reduced proportion experiencing SRE, 65 vs 46% (P < 0.001) Hortobagyi et al. [2]
3–4 weekly Delay in first SRE, 7.0 vs 13.1 months (P = 0.0005)
Pamidronate, 60 mg intravenously 401 Increased median time to skeletal progression, Hultborn et al. [15]
monthly 9 vs 14 months (P < 0.01)
Pamidronate, 90 mg intravenously 374 Reduced proportion experiencing SRE, 67 vs 56% (P = 0.027) Theriault et al. [1]
3–4 weekly Delay in first SRE, 6.9 vs 10.4 months (P = 0.049)
Ibandronate, 2/6 mg intravenously 467 Reduced SMR with 6 mg dose; 2 mg ineffective Body et al. [9]
3–4 weekly SMR, 2.18 vs 1.61 events/100 women years (P = 0.03)
SRE = skeletal related events; SMR = skeletal morbidity rate.
trials that are currently under way with zoledronic acid, clo-
dronate and ibandronate are available, the routine use of
bisphosphonates in the adjuvant setting outside of
research trials is not currently recommended except for
prevention or treatment of osteoporosis.
Conclusions and the future
There is now a much greater appreciation of the benefits
of active management of metastatic bone disease and the
options for doing so. Indeed, the success of bisphospho-
nates has focused attention on the mechanisms of the
control of bone metabolism in cancer and this is leading to
a search for new agents that might act as osteoclast
inhibitors.
One promising compound is osteoprotegerin, which is a
member of the tumour necrosis factor receptor super
family and is a natural inhibitor of osteoclast production
and activity. Osteoprotegerin acts as a decoy receptor,
binding with osteoprotegerin ligand (the natural stimulator
of osteoclast maturation) produced by the osteoblast [22].
Very recent studies in mice have shown that osteoprote-
gerin halted further bone damage and diminished the
skeletal pain associated with tumour-induced bone
destruction [23]. A synthetic preparation showed promis-
ing effects on bone resorption in normal volunteer testing
(Amgen data on file). If this promise is confirmed by phase
I clinical trials in cancer patients that are currently under
way, this long-acting, subcutaneous preparation could
have an important therapeutic role in the future.
Bisphosphonates have now been accepted as the treat-
ment of choice in hypercalcaemia of malignancy and have
an important role in reducing skeletal-related events, in
reducing bone pain and in associated analgesic use, as
well as improving quality of life. Bisphosphonates should
therefore now be considered as standard treatment in
metastatic bone disease from breast cancer. Further
research is needed to determine the best time to start
treatment, but once treatment has commenced it should
be continued for as long as the skeleton is the dominant
site of metastasis. The future may see further develop-
ments in the range of bisphosphonates available as well
as the use of biochemical markers to tailor treatment to
individual patients.
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